Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11.
about
Pulmonary metabolism of resveratrol: in vitro and in vivo evidenceMolecular Insights into Microbial -Glucuronidase Inhibition to Abrogate CPT-11 ToxicityChemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging TreatmentsIrinotecan-induced mucositis is associated with changes in intestinal mucinsHigh-performance liquid chromatographic assay for glucuronidation activity of 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan (CPT-11), in human liver microsomes.Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein.Pharmacogenetics of irinotecan: An ethnicity-based prediction of irinotecan adverse events.Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies.The impact of pharmacogenomics on gastrointestinal cancer therapy.Understanding and modulating mammalian-microbial communication for improved human health.Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2Comet assay measures of DNA damage as biomarkers of irinotecan response in colorectal cancer in vitro and in vivoIntestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage.Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer.Investigation into the Efficacy of Val-SN-38, a Valine-Ester Prodrug of the Anti-Cancer Agent SN-38.Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer.Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study.Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.Injectable SN-38-loaded Polymeric Depots for Cancer Chemotherapy of Glioblastoma Multiforme.A novel in vitro platform for the study of SN38-induced mucosal damage and the development of Toll-like receptor 4-targeted therapeutic options.Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives.A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan.Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil.Irinotecan-induced muscle twitching from a possible drug interaction: A case report.Irinotecan (CPT-11): a brief overview.Liquid Chromatographic Method for Irinotecan Estimation: Screening of P-gp Modulators.Rapid deconjugation of SN-38 glucuronide and adsorption of released free SN-38 by intestinal microorganisms in rat.Irinotecan: a new antineoplastic agent for the management of colorectal cancer.Current perspectives on camptothecins in cancer treatmentIn vivo bioassay to detect irinotecan-stabilized DNA/topoisomerase I complexes in rats.Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile.Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients.Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients.Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer.Circadian rhythm of irinotecan tolerability in mice.Loperamide inhibits the biliary excretion of irinotecan (CPT-11) in the rat isolated perfused liver.Prevention of irinotecan-induced diarrhea by oral sodium bicarbonate and influence on pharmacokinetics.Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats.Irinotecan-induced colitis.
P2860
Q24633218-531FFB3D-7C2F-479E-B6DF-75BA9EDC411FQ27678202-1662476A-F0BA-44F0-AC58-C980D97EDC80Q28079705-628ED09A-5BBD-4AF5-8BA2-4965193ED24BQ28577295-95BA44A9-BEEC-447A-B8BB-9E1AE94A31B3Q31002893-ECD71BD5-8704-4C51-A9BA-34EFBF3BC9ABQ33267448-DA4B2186-DFB1-43D7-A7A7-0F64E5CDCCE2Q34391234-33CC463D-1AF7-463F-B07E-EECC4C26BFC3Q34512245-B4A56868-7068-4FBA-955D-8735AD5422B4Q34837030-9C981EF7-455E-487F-B5F6-277212700659Q35026463-659CCE8E-BF57-4B3A-81A3-E4FEABEE0E6FQ35051651-46497262-D516-4DFF-934F-8DABEBD115B5Q36051757-131B8637-F87F-4B30-8EF9-592251CD36F0Q36384554-B9752E34-496A-49D4-9537-A93ADD1FB238Q37187386-F54FA0F8-53E8-46EF-835B-DC34E672C7FFQ37224592-1DA41122-B333-40AF-862E-79BE212B64FCQ37378223-A617DD82-D9B0-4FA1-BB2A-9C19E6AC7298Q37402459-436ED11A-0C62-489A-845F-00A13D40A7E0Q37441604-82ABF04F-ECC0-4B7E-B8F4-899FFFC79C87Q37697523-9B49CEDE-ED41-4F9F-8A76-2BCD7F145869Q38734048-E9AF8C05-761E-4F2C-BD3E-B4694FE8E3E4Q38781452-FF939604-4AC7-4B43-AA72-E0D6DA4EA142Q38945299-6D56E5AF-99F4-4CF1-90D2-14896FDC2A2EQ39139284-89D3AD09-33DD-4311-81EA-515BC970515DQ40024970-1B4F71BF-1D9E-460E-897D-DE3066ED569FQ40107303-AD123981-49FD-45BC-93E1-27D37145B63AQ41205252-51C34F00-1562-4290-BA5F-9343AE1F9B1CQ41231401-2277750B-9D16-4ABB-95D1-67574D08E049Q42180635-B4FE9AE7-8EDB-42DF-9063-A994EEE4CC90Q42689180-B6ECA8A8-51BE-46C9-8DC4-43EC302D3053Q42715927-3DA4F0FC-959F-4B55-8994-3AAF5CA0FB6AQ43137579-FBC9AE50-33D8-46C8-ACC1-D3F240EAF1EDQ43274557-C8C94F62-47CA-4599-9F7C-065E4081ABFFQ43342861-9309CDE2-E1D4-4F61-9AFC-405E0E965226Q44010193-65182077-66C2-4381-90C9-C0671C1B12A3Q44545189-23063CD0-9A4D-4EB4-8B23-54D61FF2F618Q45095461-67771485-FCFC-4C3B-A4CE-C34FBCB58207Q45216034-8D41FEF9-0D47-48AD-A86F-A0EB5EA52C7FQ45267582-B0B2743F-9898-47B0-9B51-B765C99662DFQ46413208-F7761FDC-A7A9-4264-A3C8-2026932531B8Q46466616-20DA3E23-1B8E-437F-9EF3-BF037FE199F3
P2860
Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh
1993年學術文章
@zh-hant
name
Relationship between developme ...... neal administration of CPT-11.
@en
Relationship between developme ...... neal administration of CPT-11.
@nl
type
label
Relationship between developme ...... neal administration of CPT-11.
@en
Relationship between developme ...... neal administration of CPT-11.
@nl
prefLabel
Relationship between developme ...... neal administration of CPT-11.
@en
Relationship between developme ...... neal administration of CPT-11.
@nl
P2093
P2860
P1476
Relationship between developme ...... neal administration of CPT-11.
@en
P2093
P2860
P304
P356
10.1111/J.1349-7006.1993.TB02031.X
P577
1993-06-01T00:00:00Z